MarketAxess Holdings operates a leading electronic trading platform that enables fixed-income market participants to efficiently trade corporate bonds and other types of fixed-income instruments. The company was founded in 2000 and is based in New York, New York.
Ipsen (Euronext: IPN; ADR: IPSEY), today announced the primary analysis of the Phase I/II study evaluating the investigational use of irinotecan liposome injection (Onivyde®) in combination with 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) together, known as NALIRIFOX in study patients with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC) during a late-breaking oral presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGI), 1–5 July 2020. The results include safety and efficacy analyses from the multicenter, open-label, study consisting of dose-exploration safety run-in (traditional 3+3 design) to confirm the maximum tolerated dose and appropriate dose regimen for NALIRIFOX in the dose-expansion phase.1
By Fran Rodilosso, Head of Fixed Income ETF Portfolio Management, CFA, VanEck Global A transformation is underway in the fixed income market, sparked by the growing adoption of electronic bond trading. We caught up with the team at MarketAxess, an electronic trading platform for fixed income trading. MarketAxess shared some interesting insights on how rapidly the market […] The post The Electronification of Emerging Markets Bond Trading appeared first on ETF Trends .